Carregant...

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

The limited prognosis of patients with castration-resistant prostate cancer (CRPC) on existing hormonal manipulation therapies calls out for the urgent need for new management strategies. The novel, orally available, small-molecule compound, abiraterone acetate, is undergoing evaluation in early cli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ang, J E, Olmos, D, de Bono, J S
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2009
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653756/
https://ncbi.nlm.nih.gov/pubmed/19223900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604904
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!